Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 20;8:631. doi: 10.1038/s41467-017-00662-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — Performance and relative abundances of the potential N-glycan biomarkers for RA. a Symbols depicting N-glycan biomarkers identified in current study (SGm1 and SGm2) and that reported previously (G0/G1). b The ROC curve of the biomarkers for the classification of RA (n = 90) and healthy individuals (n = 57). The results are plotted for the training set. c, d The scatter plot of the relative abundance of the N-glycan biomarker in control individuals (training set: n = 57, validation set: n = 84), RF-positive [RA (RF+)] (training set: n = 71, validation set: n = 90) and RF-negative [RA (RF−)] RA patients (training set: n = 19, validation set: n = 97), as well as ACPA-positive [RA (ACPA+)] (training set: n = 75, validation set: n = 132) and ACPA-negative [RA (ACPA−)] RA patients (training set: n = 15, validation set: n = 55), in training set and validation set. e The scatter plot of the relative abundance of the N-glycan biomarkers in AS patients (n = 34), OA patients (n = 26) and in controls of each (AS: n = 27, OA: n = 45). Horizontal lines indicate the median. Statistical analysis was performed by non-parametric Mann–Whitney test, two-sided (*P < 0.05, **P < 0.01, ***P < 0.001)